Compare GGAL & RYTM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | GGAL | RYTM |
|---|---|---|
| Founded | 1905 | 2008 |
| Country | Argentina | United States |
| Employees | 10079 | N/A |
| Industry | Commercial Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.6B | 6.2B |
| IPO Year | N/A | 2017 |
| Metric | GGAL | RYTM |
|---|---|---|
| Price | $49.72 | $83.88 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 14 |
| Target Price | $69.00 | ★ $131.14 |
| AVG Volume (30 Days) | ★ 1.3M | 692.5K |
| Earning Date | 03-07-2023 | 05-05-2026 |
| Dividend Yield | ★ 3.70% | N/A |
| EPS Growth | N/A | ★ 28.34 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $62.29 | $55.34 |
| Revenue Next Year | $22.88 | $86.06 |
| P/E Ratio | $13.36 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $25.89 | $60.71 |
| 52 Week High | $62.11 | $122.20 |
| Indicator | GGAL | RYTM |
|---|---|---|
| Relative Strength Index (RSI) | 63.42 | 41.68 |
| Support Level | $47.86 | $82.31 |
| Resistance Level | $50.20 | $90.79 |
| Average True Range (ATR) | 2.07 | 3.80 |
| MACD | 1.07 | -0.60 |
| Stochastic Oscillator | 81.51 | 7.57 |
Grupo Financiero Galicia SA is a financial service holding company. It provides general banking services, proprietary brand credit card services, personal loans, insurance, and other services. The company's operating business segments are Banks, Ecosistema Naranja X, Insurance, Adjustments, and Other Businesses. The company generates maximum revenue from Banks. Geographically its operate in Argentina, Uruguay, and the majority of its revenue comes from Argentina.
Rhythm Pharmaceuticals Inc is a commercial-stage biopharmaceutical company engaged in the development and commercialization of therapies for patients with rare neuroendocrine diseases. The company is focused on advancing its melanocortin-4 receptor (MC4R) agonists, including its main asset, IMCIVREE (setmelanotide), as a precision medicine designed to treat hyperphagia and severe obesity caused by rare MC4R pathway diseases. In addition, it has two early-stage investigational MC4R agonists in clinical development, RM-718 and bivamelagon, designed not to cause hyperpigmentation. The company is also focused on advancing potential candidates for congenital hyperinsulinism. It currently operates in two business segments: the United States, which generates maximum revenue, and International.